Cargando…

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database

BACKGROUND: Our previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children. However, the actual clinical situation has not been clearly elucidated. In this pap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Masataka, Horiuchi, Hideki, Torii, Tomoko, Nakajima, Akihiro, Iijima, Takeshi, Murano, Hiroshi, Yamanaka, Hisashi, Ito, Shuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684120/ https://www.ncbi.nlm.nih.gov/pubmed/34922491 http://dx.doi.org/10.1186/s12887-021-03051-x

Ejemplares similares

Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
por: Ito, Shuichi, et al.
Publicado: (2020)

Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
por: Koto, Ruriko, et al.
Publicado: (2021)

Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data
por: Koto, Ruriko, et al.
Publicado: (2020)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations
por: Stewart, Sarah, et al.
Publicado: (2016)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Brief Report: Monosodium Urate Monohydrate Crystal Deposits Are Common in Asymptomatic Sons of Patients With Gout: The Sons of Gout Study
por: Abhishek, Abhishek, et al.
Publicado: (2018)

Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition
por: Hisatome, Ichiro, et al.
Publicado: (2023)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis
por: Zhu, Junyu, et al.
Publicado: (2020)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
por: Toyoda, Yu, et al.
Publicado: (2019)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Susceptibility genes of hyperuricemia and gout
por: Nian, Yue-Li, et al.
Publicado: (2022)

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout
por: Toyoda, Yu, et al.
Publicado: (2021)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
por: Pálinkás, Márton, et al.
Publicado: (2022)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development
por: Kim, Hye Won, et al.
Publicado: (2022)

Medical Students’ Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study
por: Zuzic Furlan, Sanja, et al.
Publicado: (2021)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

An update on the genetic architecture of hyperuricemia and gout
por: Merriman, Tony R
Publicado: (2015)

Pharmacological effects of Chatuphalatika in hyperuricemia of gout
por: Sato, Vilasinee Hirunpanich, et al.
Publicado: (2018)

The role of the Mediterranean diet in hyperuricemia and gout
por: Stamostergiou, Julie, et al.
Publicado: (2018)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function
por: Jeon, Hee Jung, et al.
Publicado: (2019)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
por: Zhang, Lin, et al.
Publicado: (2022)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
por: Sapankaew, Tunlanut, et al.
Publicado: (2022)

Burden and distribution of monosodium urate deposition in patients with hyperuricemia and gout: a cross-sectional Chinese population-based dual-energy CT study
por: Zhang, Xin-Yu, et al.
Publicado: (2023)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d7deb8blm4tspgu8sei2001j0k